PHILADELPHIA - Direct purchasers cannot establish as a matter of law an overall antitrust conspiracy to restrain trade in the modafinil market based on bilateral reverse settlement agreements between prescription drug manufacturer Cephalon and four generic drug manufacturers, a federal judge in Pennsylvania ruled June 23 in granting motions for summary judgment filed by Cephalon and the generic defendants and denying the motion for summary judgment filed by the direct purchaser class plaintiffs (King Drug Company of Florence, Inc., et al. v. Cephalon, Inc., et al., No. 2:06-cv-1797, E.D. Pa.; Vista Healthplan, Inc., et al. v. Cephalon, Inc., et al., No. 2:06-cv-1833, E.D. Pa.; Apotex, Inc. v. Cephalon, Inc., et al., No. 2:06-cv-2768, E.D. Pa.; 2014 U.S. Dist. LEXIS 84818).